Parnax Lab

Parnax Lab EBIT CAGR 3Y

The EBIT CAGR (3 Year) of Parnax Lab (506128.BO) as of Nov 14, 2026 is 4.81 %. In the previous year, EBIT CAGR (3 Year) was 4.81 % — a change of 0.00% (lower).

EBIT CAGR 3Y

4.81 %

YoY

0.00%

Last updated:

EBIT CAGR (3 Year) of Parnax Lab is 2025 4.81 % . EBIT CAGR (3 Year) of Parnax Lab was 2024 4.81 % . It decreases by 0.00% lower compared to the previous year.

The Parnax Lab EBIT CAGR 3Y history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT CAGR 3Y
Date
EBIT CAGR 3Y
Jan 1, 2018
4.81 INR
Jan 1, 2019
4.81 INR
Jan 1, 2020
4.81 INR
Jan 1, 2021
4.81 INR
Jan 1, 2022
4.81 INR
Jan 1, 2023
4.81 INR
Jan 1, 2024
4.81 INR
Jan 1, 2025
4.81 INR
The Parnax Lab EBIT CAGR 3Y history
YEAREBIT CAGR 3YYoY
4.81 %0.00%
4.81 %0.00%
4.81 %0.00%
4.81 %0.00%
4.81 %0.00%
4.81 %0.00%
4.81 %0.00%
4.81 %0.00%
4.81 %0.00%
4.81 %0.00%
4.81 %0.00%
4.81 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Parnax Lab Stock analysis

What does Parnax Lab do? Parnax Lab Ltd. generates revenue through manufacturing and exporting pharmaceutical formulations, including cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, geriatric special formulations, highly viscous products, and suspensions. The company trades pharmaceuticals and medicinal products, focusing on high-volume oral formulations for diverse consumer segments. Naxpar Pharma Private Limited serves as its subsidiary in these operations. The firm's primary customers are likely healthcare providers, pharmacies, and distributors within the pharmaceutical industry, though specific buyer details are not disclosed. Parnax Lab Ltd. operates through the pharmaceutical formulations segment, emphasizing export-driven manufacturing and trading activities. Its product portfolio targets various health needs, from pediatric to geriatric care, with a strong focus on oral delivery systems. Parnax Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Parnax Lab stock

EBIT CAGR (3 Year) of Parnax Lab is 4.81 % in 2025.

On Eulerpool you can find the complete historical development of EBIT CAGR (3 Year) Parnax Lab since 2006 – with annual values, charts, and detailed analysis.

The 3-year EBIT CAGR shows the compound annual growth rate of EBIT over the past three years.

To evaluate EBIT CAGR (3 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT CAGR (3 Year).

EBIT CAGR (3 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT CAGR (3 Year)'s Parnax Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Parnax Lab

All Key Metrics — Parnax Lab